Last updated 26 May 2026
Overview
VDPHL01 is an extended-release (ER) oral formulation of minoxidil, developed by Veradermics for pattern hair loss (androgenetic alopecia). The active molecule, minoxidil, is a decades-old, well-characterised hair-growth agent. What is new about VDPHL01 is not the drug but the delivery: a proprietary gel-matrix that controls how minoxidil is released into the bloodstream. The mechanism described below is therefore well established — not speculative.
How VDPHL01 promotes hair growth
- Local activation. Minoxidil is a prodrug. In the hair follicle, the enzyme SULT1A1 (a sulfotransferase) converts it into its active form, minoxidil sulfate.
- Vasodilation and follicle stimulation. Minoxidil sulfate opens ATP-sensitive potassium channels and acts as a vasodilator, increasing blood flow to the follicle.
- Longer growth phase. This prolongs the anagen (active growth) phase and helps reverse the miniaturisation of affected follicles, producing thicker, longer hairs.
- Exposure-dependent effect. The response is time- and exposure-dependent: the longer active minoxidil sulfate is present at the follicle, the greater the hair-growth effect.
Why it is non-hormonal
Unlike finasteride and dutasteride, minoxidil does not inhibit 5-alpha-reductase and does not change testosterone or DHT levels. It acts directly on the follicle and its blood supply, not on the hormonal axis. This is why VDPHL01 avoids the sexual and mood-related side effects associated with hormonal hair-loss drugs — the same reason topical minoxidil has always been hormone-neutral.
The extended-release advantage
This is the core of VDPHL01. Standard immediate-release (IR) oral minoxidil produces a high peak plasma concentration (Cmax) that is linked to cardiac side effects — fluid retention, pericardial effusion — and limits how high the dose can safely go.
- There is roughly a 10× gap between the plasma level needed for hair growth (~1.62 ng/mL) and the level associated with cardiac activity (~20 ng/mL).
- VDPHL01’s gel-matrix flattens the peak below the cardiac threshold, while delivering nearly twice the total minoxidil exposure over 12 hours and keeping levels above the hair-growth threshold about twice as long as a 2.5 mg IR tablet.
- The result is more consistent, longer-lasting exposure of the follicle to active drug — designed to raise efficacy while minimising cardiac risk.
Pharmacokinetic profile
- Engineered to keep peak plasma minoxidil below the ~20 ng/mL cardiac-activity threshold.
- Maintains levels above the ~1.62 ng/mL hair-growth threshold roughly twice as long as 2.5 mg IR minoxidil.
- Delivers approximately 2× total minoxidil exposure over 12 h versus a 2.5 mg IR tablet.
Source: Veradermics Corporate Presentation (May 2026); plasma data from study QSC300720.
From mechanism to results
In Phase 2/3 Study ‘302’, this design translated into a mean increase of +30.3 to +33.0 hairs/cm² at 6 months versus +7.3 for placebo, with no cardiac adverse events of special interest — consistent with the goal of separating the hair-growth effect from the cardiac one. For trial design and full results, see the Clinical Trials page.
Sources
- Veradermics Corporate Presentation, May 2026 (mechanism and pharmacokinetics).
- ClinicalTrials.gov: NCT06724614 (Study ‘302’).
- Established minoxidil pharmacology: SULT1A1 activation to minoxidil sulfate; potassium-channel opening and vasodilation at the follicle.